Weed (BUDZ) Capital Expenditures (2010 - 2023)

Weed (BUDZ) posted quarterly Capital Expenditures of $10000.0 for Q1 2023, down 96.26% quarter-over-quarter from $267499.0 in Q4 2021.

Weed (BUDZ) Capital Expenditures (2010 - 2023) Analysis & Trends

Weed's Capital Expenditures history runs 8 years deep, the most recent figure standing at $10000.0 for Q1 2023.

In Q1 2023, Capital Expenditures changed N/A year-over-year to $10000.0; the TTM figure through Dec 2023 stood at $10000.0 (changed N/A YoY), while the FY2023 annual figure was $10000.0, changed N/A from the prior year.
Capital Expenditures for Q1 2023 stood at $10000.0, down from $267499.0 in the prior quarter.
The five-year high for Capital Expenditures was $267499.0 in Q4 2021, with the low at -$163590.0 in Q3 2020.
The 4-year median for Capital Expenditures is $6867.0 (2021), against an average of $47368.7.
The sharpest annual moves came in 2019 and 2021: Capital Expenditures sank 99.13% in 2019, then surged 63.52% in 2021.
Weed's Capital Expenditures stood at $2979.0 in 2019, then soared by 5391.44% to $163590.0 in 2020, then soared by 63.52% to $267499.0 in 2021, then tumbled by 96.26% to $10000.0 in 2023.
Business Quant data shows BUDZ's Capital Expenditures at $10000.0 in Q1 2023, $267499.0 in Q4 2021, and $3734.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	104.00 Mn
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	117.00 Mn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-337.60 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	108.00 Mn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	52.80 Mn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	7.80 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	33.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Weed	4.08 Mn	4.08 Mn	-	-

Download Data